{"id":59883,"date":"2026-03-18T16:07:08","date_gmt":"2026-03-18T08:07:08","guid":{"rendered":"https:\/\/flcube.com\/?p=59883"},"modified":"2026-03-18T16:07:09","modified_gmt":"2026-03-18T08:07:09","slug":"ark-biopharma-files-hong-kong-ipo-roche-licensed-rsv-and-ipf-pipeline-targets-respiratory-and-pediatric-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59883","title":{"rendered":"Ark Biopharma Files Hong Kong IPO \u2013 Roche\u2011Licensed RSV and IPF Pipeline Targets Respiratory and Pediatric Markets"},"content":{"rendered":"\n

Shanghai Ark Biopharmaceutical Co., Ltd.<\/strong> has submitted an initial public offering (IPO) filing<\/strong> to the Hong Kong Stock Exchange<\/strong>, seeking capital markets access to advance its six\u2011candidate pipeline<\/strong> focused on respiratory diseases and pediatric conditions<\/strong>, anchored by two Roche\u2011licensed core assets<\/strong> approaching regulatory and clinical inflection points.<\/p>\n\n\n\n

Corporate & Pipeline Overview<\/h2>\n\n\n\n
Attribute<\/th>Detail<\/th><\/tr><\/thead>
Founded<\/strong><\/td>2013<\/td><\/tr>
Headquarters<\/strong><\/td>Shanghai, China<\/td><\/tr>
Therapeutic Focus<\/strong><\/td>Respiratory diseases; pediatric conditions<\/td><\/tr>
Pipeline Scale<\/strong><\/td>6 drug candidates<\/strong><\/td><\/tr>
Core Assets<\/strong><\/td>Ziresovir (RSV); AK3280 (IPF)<\/td><\/tr>
Licensing Strategy<\/strong><\/td>In\u2011licensing from Roche\/Genentech\/InterMune<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Core Product Profile<\/h2>\n\n\n\n

Ziresovir \u2013 RSV Therapeutic<\/h3>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Indication<\/strong><\/td>Respiratory syncytial virus (RSV) infection<\/td><\/tr>
Target Population<\/strong><\/td>Infants aged 1\u201124 months<\/strong><\/td><\/tr>
Origin<\/strong><\/td>In\u2011licensed from Roche<\/strong> (January 2014)<\/td><\/tr>
Development Stage<\/strong><\/td>NDA under review<\/strong> by China NMPA<\/td><\/tr>
Regulatory Status<\/strong><\/td>Pending approval \u2013 potential first\u2011in\u2011class RSV antiviral for infant population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

AK3280 \u2013 Idiopathic Pulmonary Fibrosis<\/h3>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Indication<\/strong><\/td>Idiopathic pulmonary fibrosis (IPF)<\/td><\/tr>
Origin<\/strong><\/td>In\u2011licensed from Roche, Genentech, and InterMune<\/strong> (August 2018)<\/td><\/tr>
Development Stage<\/strong><\/td>Phase II<\/strong> (post\u2011proof\u2011of\u2011concept)<\/td><\/tr>
Clinical Status<\/strong><\/td>PoC established; expansion\/enrollment ongoing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Investment Thesis<\/h2>\n\n\n\n
Dimension<\/th>Ark Bio Position<\/th>Market Context<\/th><\/tr><\/thead>
RSV Market Opportunity<\/strong><\/td>Ziresovir NDA pending \u2013 potential 2026\u20112027 China approval<\/td>No approved RSV antivirals for infants globally; estimated US$1.5\u20112 billion<\/strong> pediatric RSV market by 2030<\/td><\/tr>
IPF Competitive Landscape<\/strong><\/td>AK3280 Phase II vs. established nintedanib\/pirfenidone<\/td>IPF market US$3+ billion<\/strong> annually; significant unmet need for disease\u2011modifying therapies with improved tolerability<\/td><\/tr>
Roche Relationship<\/strong><\/td>Two major in\u2011licensing transactions<\/td>Validation of asset quality; potential ongoing collaboration leverage<\/td><\/tr>
Pediatric Focus<\/strong><\/td>Ziresovir infant indication; pipeline orientation<\/td>Underserved therapeutic area with regulatory incentives (pediatric priority review vouchers, NMPA fast\u2011track)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n